T. Rowe Price Associates
VTAE

T. Rowe Price Associates’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

T. Rowe Price Associates’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-50,156
Closed -$541K – 2596
2016
Q2 		$541K Hold
50,156
– – ﹤0.01% 1940
2016
Q1 		$333K Hold
50,156
– – ﹤0.01% 2120
2015
Q4 		$908K Sell
50,156
-94,128
-65% -$1.3M ﹤0.01% 1728
2015
Q3 		$1.59M Buy
+144,284
New +$1.53M ﹤0.01% 1587
2015
Q2 		– Sell
-32,332
Closed -$379K – 2585
2015
Q1 		$379K Buy
+32,332
New +$436K ﹤0.01% 2082

Other funds holding VTAE

AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $449M AUM 51.52% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates's VTAE Position: Q3 2016 in Review

T. Rowe Price Associates sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q3 2016, closing a stake of 50,156 shares — an estimated $541K sold.

T. Rowe Price Associates first reported a position in VTAE in Q1 2015 and held it in 5 quarters. The position peaked at $1.59M in Q3 2015. 98 funds tracked by Wall St. Rank hold VTAE as of Q3 2016.

  • T. Rowe Price Associates reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q3 2016 after selling out during the quarter.
  • T. Rowe Price Associates sold 50,156 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q3 2016, an estimated $541K.
  • T. Rowe Price Associates first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 5 quarters.
  • T. Rowe Price Associates's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $1.59M in Q3 2015.
  • 98 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q3 2016.

Based on T. Rowe Price Associates's 13F filing for Q3 2016, filed 14 Nov 2016.